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Abstract 
Throughout the years monitoring and therapy of diabetes was significantly changing. Undoubtedly, 
a definite improvement of applied technologies not only increased the average life expectancy of 
diabetic patients but also influenced their comfort. The purpose of the study was to present the 
history of methods diagnosis and treatment of diabetes. Additionally, promising modern medical 
technologies were reviewed. Nanotechnology, modern robots and transplants of pancreatic islets are 
currently under experiments showing satisfactory results. These technologies enable monitoring of 
glucose level, prevent hypoglycemia and sustain normoglycemia. Moreover, surgical attempt 
involving transplantation give a chance to counter the complications followed by diabetes 
development.  
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Introduction 
A development of 21st century medicine seems to be seems to be inextricably linked to 
improvement of technology. Genomics, medical robotics, nanomedicine, telemedicine and many  
other areas may be mentioned in which these two disciplines cannot exist without each other. A 
visible trend is moving away from treatment developed on the basis of a lock and key mechanism, 
 95 
as in the case of antibiotic therapy or any other pharmacotherapy acting on a specific point of grip. 
Beginning of current century was an initiative point of intensive development of immunology and 
highly advanced medical technologies
1
. Scientists around the world compete against each other  in 
creating new diagnostic and therapeutic methods that provide the highest possible comfort for the 
patient and improve both - diagnosis and treatment of civilization diseases.  
 
What is diabetes? 
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from 
impaired insulin secretion or activity. Chronically occurring hyperglycemia causes damage, 
malfunction and failure of various organs. In recent decades, the number of people with diabetes 
has significantly increased. In 1980 the patients number was estimated to 108 million, while in 2014 
this amount was already about four times higher. Considering the data presented by WHO, the 
global incidence of diabetes in 2014 among people over 18 was 422 million cases reported.  
 
Diabetes type 1 is the most common form of the disease (90%) especially in case of children and 
adolescents in many Western populations. Additionally, white race is more commonly affected. 
However, considering all age groups - type 1 diabetes emerges in 5-10% of diabetics. It is 
statistically estimated that around 80,000 children up to the age of 15 are diagnosed with type 1 
diabetes every year
2
. Over past decades, a global increase in the incidence of type 1 diabetes has 
been observed due to the escalation of the world population and elongated average age of the 
population. Such pattern is correlated with the increased percentage of people with HLA genotype 
at risk of developing the disease.This may suggest an increasing impact of environmental factors on 
the disease emergence
34
. The incidence of type 1 diabetes varies widely across countries, between 
them and between ethnically different populations. Statistically, the highest values were denoted in 
Finland, Northern Europe
5
 and Canada
6
. Considering the latest recommendations of the Polish 
Diabetes Association (PDA), the overall goal of glycemic control expressed as HbA1c should be 
<6.5% (53 mmol / mol). The purpose of the article is to present the modern blood glucose control 
methods that aim to achieve this value.  
 
How was it in the past?  
Last century was undoubtedly a breakthrough time in the field of diabetes and inventing modern 
methods of glucose control. Until 1950, the Benedict test was the only possible way to measure 
blood glucose levels
7
. In 1953 the urine tablets appeared and few years later stripes were introduced 
to assess the glucose values in urine. In 1955 the first sulfonylurea derivatives appeared whereas in 
1959 the method of determining insulin level in the body of patients was developed. It was then 
discovered that some patients were still producing their own insulin. It was then discovered that 
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some patients were still producing their own insulin. That is how the concepts of insulin-dependent 
diabetes mellitus (type 1) and insulin-independent diabetes mellitus (type 2) arose. The first 
glucometer appeared in 1970, manufactured by the Ames Company. In 1958, a new parameter, 
glycated - glycosylated hemoglobin (HbA1C), was discovered and introduced as a standard method 
for measuring long-term diabetes control. 
 
The need of monitoring of blood glucose level forces diabetic patients to collect small blood 
samples, often several times a day. Considering the long-term course of the disease, the standard 
monitoring methods available to date have caused a great deal of discomfort to patients, due to the 
need to frequent interruption of skin continuity. The development of medical technology has 
enabled the use of continuous blood glucose monitoring using nanorobots
8
. The application of 
nanotechnology not only improves the quality of life of patients and free them from the obligation 
of regular glucose levels checks or frequent laboratory tests. In addition, it ensures ongoing control 
of the patient's parameters by a doctor who receives current data on the patient's condition from the 
device. 
 
Modern technologies in diabetes monitoring  
Nanotechnology is a powerful tool that enables the development of devices for monitoring blood 
glucose, in particular using nanorobots. They are the basic means used in modern devices used for 
measuring glucose. An example of the external structure of a nanorobot includes a thin coating, 
reminiscent of diamond in structure and physical properties
9
. It is covered with an artificially 
created layer of glycocalyx, which ensures a reduction in adsorption and bioactivity in relation to 
fibrinogen and other proteins found in the blood
1011
. This enables the highest possible level of 
biocompatibility to avoid the immune system reaction against foreign body
12
. The construction of 
nanorobots has the appropriate properties to ensure the identification of devices by the transponder 
system using radio frequencies. That results in determination of their correct location and data 
reading - most often using customized applications
13
.  
 
Proper monitoring of blood glucose level by nanorobot is possible due to presence of chemosensor. 
This device uses the modulated human protein carrier SGLT3 and serves as a transmitter that 
identifies glucose
14
. The medical nanorobot should adapt its structure and functionality to ensure 
compatibility with typical medical applications. Such approach enables synchronous operation of 
the antenna, reader and nano processor and maintains compactness, putting all necessary elements 
in one chip
15
. 
 
Currently, many research groups are working on introducing all kinds of new technologies to the 
market in order to improve patient comfort during daily, mandatory glucose measurements. These 
are easy-to-use devices such as contact lenses, eMosquito, saliva analyzers, tattoos and ear pads. 
                                                 
8
 Cavalcanti A, Shirinzadeh B, Kretly LC, Medical nanorobotics for diabetes control. Nanomedicine: NBM (2008), 
4:127-138. 
9
 Narayan RJ. Pulsed laser deposition of functionally gradient diamond- like carbon-metal nanocomposites. Diam Relat 
Mat (2005), 14:1319-1330. 
10
 Freitas Jr RA. Nanotechnology, nanomedicine and nanosurgery. Int J Surg (2005), 3:1-4. 
11
Marchant RE, Zhang T, Qiu Y, Ruegsegger MA. Surfactants that mimic the glycocalyx. United States patent US 
6759388; 1999. 
12
 Grieninger G, Fu Y, Cao Y, Ahadi MZ, Kudryk B. Monospecific antibodies against a subunit of fibrinogen. United 
States patent US 6025148; 2000. 
13
 Ahuja SP, Myers JR. A survey on wireless grid computing. J Supercomput (2006), 37:3-21. 
14
 Wright EM, Sampedro AD, Hirayama BA, Koepsell H, Gorboulev V, Osswald C. Novel glucose sensor. United 
States patent US 0267154; 2005. 
15
 Cavalcanti A, Shirinzadeh B, Freitas Jr RA, Hogg T. Nanorobot 
architecture for medical target identification. Nanotechnology (2008), 19(015103: 15. 
 97 
 
For example, several research groups are currently working on introducing contact lenses with 
built-in biosensors for continuous and non-invasive monitoring of glucose levels in the secretion of 
tear glands. In biosensors boronic acids are used, which bind to groups containing diols, such as 
carbohydrates, thus forming boronates
16
. These sensors built into the device can diffract light, so 
that any change in blood glucose will change the color of the light. Then, the patient can determine 
the glucose result by checking the color of the contact lens sensor using a device containing a white 
light source, mirror and color card. In a similar manner, boric acid derivatives can be designed to 
detect glucose by fluorescence. Boronic acid fluorophores induce spectral changes in the presence 
of sugars. These fluorophores can be introduced into disposable commercial contact lenses by 
incubating for 24 hours and then washing with water to remove excess dye. Another aspect in favor 
of this method, in economic terms, is the low cost of producing gel from boronic acid
17
. 
 
Scientists from the University of Calgary have developed eMosquito, which in action is supposed to 
resemble a mosquito bite
18
. The goal is to control blood glucose levels in the least invasive way. 
The device comes in the form of bracelets that include six small needles which puncture the skin in 
a way that does not threaten nerve irritation nor causes pain. Punctures are sequential and occur at 
pre-programmed intervals. Due to the sensors connected with the needles it is possible to control the 
level of glucose in the blood several times a day. Recorded data can be sent automatically to a 
telephone or computer. This device is still being tested
19
. 
 
GlucoTrack is another device available on the market for non-invasive blood glucose measurement. 
This device monitors changes in glucose concentration in the earlobe using three technologies: 
ultrasonic, thermal and electromagnetic. These parameters change due to shifts in compressibility 
and hydration of cellular and extracellular tissue of the earlobe that are associated with changes in 
glucose concentration
20
. The earlobe tissue consists of three layers: epidermis, dermis and 
subcutaneous tissue. These layers differ in the volume of blood plasma that may affect the delay of 
glucose dynamics between these layers
21
. This delay depends mainly on blood perfusion, which 
affects vascular permeability
22
. According to the studies conducted by Tamar Lin, Yulia Mayzel, 
Karnit Baharta, the influence of factors that may cause microvascular complications on the 
occurrence of glucose dynamics delay
23
.  The results showed that factors such as diabetes duration, 
smoking history and HbA1c levels do not significantly affect device accuracy. Demographic factors 
such as age, gender, body weight, and ear piercing affect GlucoTrack performance, which further 
supports the usefulness of people with type 2 diabetes. In these studies, the accuracy of the device 
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was comparable for people with different clinical characteristics, indicating that it is suitable for 
different people with type 2 diabetes
24
. 
 
What is more, scientists from Hong Kong Polytechnic University in China have created an 
accessible biosensor that measures glucose in human saliva for common use
25
. It is a microfluidic 
analytical device which in combination with systems on smartphones is considered an effective tool 
for the diagnosis of biomarkers in oral fluid. Available graphene oxide coated nanomaterials are 
combined with smartphone colorimetric detection and used to directly quantify glucose. By means 
of a self-developed application, glucose levels in the physiological range can be automatically 
quantified. During the tests, the system was used to quantify glucose levels in artificial saliva and 
the results obtained using a portable system showed compliance with real concentrations
26
. 
 
In 2016, experiments were conducted in order to introduce a glucose level sensor into a handheld 
breathalyzer that measures the concentration of organic components in the breath
27
. According to 
researchers from "Western New England University", early clinical results showed clear 
correlations between blood glucose and breath-induced acetone. The study using a hand-held 
breathalyzer involved the patient blowing air into a device. This device immediately read the level 
of acetone in the breath, which is closely correlated with the level of blood glucose and can be a 
completely non-invasive way to control glucose in people with diabetes
28
. Researchers of 
University of Strathclyde in Glasgow and King's College London were developing the use of 
nanosensors in form of intelligent' tattoos that can be implanted into the skin
29
. Such approach was 
definitely beneficial especially for young students. This method is permanent and the task is to 
monitor the changes in blood glucose levels as well as to signal a warning in the event of hypo- or 
hyperglycemia. These changes can be read immediately at any time, using a hand-held device, 
applied close to the skin. Similar experiments were conducted in Massachusetts Institute of 
Technology USA s regarding the creation of tattoos using a special infrared refractive ink for 
constant monitoring changes in blood glucose levels
30
.  
 
In addition to the above-mentioned innovative devices, CNoga Medical Ltd in Israel is also 
researching the use of a device that uses skin color assessment. The application of this method is not 
only limited to blood glucose levels monitoring but also it involves blood pressures 
measurements
31
. 
 
 
                                                 
24
 Bahartan K, Horman K, Gal A, et al. Assessing the performance of a non-invasive glucose monitor in people with 
type 2 diabetes with different demographic profiles. J Diabetes Res. (2017):4393497: 8. 
25
 The Hong Kong Polytechnic University. "Highly sensitive biosensor for measuring glucose in saliva." ScienceDaily. 
www.sciencedaily.com/releases/2016/04/160406075341.htm (accessed August 21, 2019). 
26
 Jia Y, Sun H, Li X, Sun D, Hu T, Xiang N, Ni Z. Paper-based graphene oxide biosensor coupled with smartphone for 
the quantification of glucose in oral fluid. Biomed Microdevices. (2018) 12;20(4):89. 
27
medGadget [Internet]. Printed sensors evaluated for glucose measurement in exhaled breath [22 Jan 2016; cited 12 
Dec 2016] 
28
Faulkner S. Handheld breathalyzer as noninvasive blood glucose monitor in development. Drug Delivery Business 
(2016), available at: https://www.drugdeliverybusiness.com/handheld-breathalyzer-noninvasive-blood-glucose-monitor-
development.  
29
John C. Pickup, B.M., D.Phil., Faaizah Khan, Ph.D., Zheng-Liang Zhi, Ph.D., Jonathan Coulter, M.Chem, and David 
J. S. Birch, Ph.D. Fluorescence Intensity- and Lifetime-Based Glucose Sensing Using Glucose/Galactose-Binding 
Protein (2013) 7(1): 62-71.  
30
Heo YJ, Takeuhi S. Towards smart tattoos: implantable biosensors for continuous glucose monitoring. Adv Healthc 
Mater. (2013), 2(1):43-56.  
31
 Zarkogianni K, Litsa E, Mitsis K, Wu P-Y, Kaddi CD, Cheng C-W, et al. A review of emerging technologies for the 
management of diabetes mellitus. IEEE Transactions on Biomedical Engineering (2015), 62(12):2735-2749.  
 99 
Innovative treatment for diabetes  
Micro- and macroangiopathy are major complications of diabetes type 1 that pose a therapeutic 
problem and require a modern approach to treatment. Despite the development of pharmacotherapy 
and a significant emphasis on patient education, the problem of nephropathy will develop in a group 
of 9-40% of patients, and retinopathy will cover 98% of them 15 years after the onset of the 
disease
32
. These data prove that the standard approach to treatment is insufficient. Concerning the 
patients with unstable and complicated type 1, transplantation of the pancreas was proposed as an 
alternative method of therapy. Over the past 10 years, 750 such operations have been performed in 
over 30 international transplant centers
33
. The most common method of surgery is transplantation of 
the pancreas with the kidneys of the donor (simultaneous pancreas-kidney (SPK)
34
. This is the 
procedure recommended by American Diabetes Association (ADA), especially for patients with 
advanced kidney disease. The beneficial effect involves not only control of normoglycemia, but 
also prevents hypoglycemia
35
. The improvement of these parameters occurs in a short period of 
time, which contributes to a significant rapid improvement in the patient's quality of life. In the 
exemplary study, the glycated hemoglobin level of each of the 37 patients before treatment was 
above normal (from 5.4% to 7.4%). After transplantation, these values decreased to 6.7% after one 
year and 6.5% after 2 years. In addition, SPK provides protection for transplanted kidneys, which 
can be seen on the basis of improving renal parameters. A cross-sectional study of eight patients 
compared urinary albumin excretion and creatinine clearance. Prior to transplantation, the median 
excretion of albumin in patients was 103 mg per day, after 5 years - 30 mg per day, and after 10 
years - 20 mg per day
36
. A decrease was also recorded for clearance - from 108 +/- 20 ml / min to 
1.73 m2 to 74 +/- 14 ml / min to 1.73 m2
37
 . There was also a difference in the average time of 
organ functioning after transplantation. after SPK it was 9 years, and after PAK (kidney 
transplantation after pancreas transplantation) -6, which also speaks for the effectiveness of this 
type of surgery. 
 
Despite satisfactory results regarding pancreas transplantation, less invasive forms of 
transplantation are currently sought for the treatment of complicated type 1 diabetes. Promising 
solution may be the transplantation of pancreatic isles exclusively as it minimizes the extent of the 
operation
38
. Donor pancreas is isolated according to the Ricordi method of controlled digestion of 
the pancreas using a dissociative apparatus. The next step involves cleaning of the islets and that 
allows  completing the amount of usage downloaded. Unfortunately, such procedure creates a 
potential risk of embolism during the transplantation. The step before the procedure is breeding, 
which allows the collection of tissues and their regeneration after completion. Isolated pancreatic 
islets are transplanted through the portal vein of the recipient under ultrasound control
39
.  
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Artificial pancreas  
An alternative to pancreatic transplantation are modern insulin pumps cooperating with sensors. 
Such an enriched pump informs the patient about the hypoglycemia with a sound signal. A breaking 
point was the introduction of automation that not only monitors blood glucose levels, but also 
counteracts hypoglycemia. The mechanism of ’artificial pancreas’ is based on insulin injection that 
follows too high glucose result detection. Substance administration is independent of the patient, 
being fully controlled by appropriate device algorithms. The main advantage of the mechanism is 
the prevention of nocturnal hypoglycemia
40
. A study comparing "artificial pancreas" known as 
BiAP (Bio-Inspired Artificial Pancreas) and traditional insulin pumps with sensors indicates that for 
the first group, the time during which the patient was in a hypoglycemic state significantly 
decreased - 17.9% to 3.0% (p<0.01). Although the average glucose level at night was lower in the 
case of ordinary pumps with sensors (4.8 mmol / L vs 7.5 mmol / L), this is an imperfect 
assessment. Such value was caused by more frequent attacks of hypoglycemia in this group
41
. In the 
case of BiAP, glucose level fluctuations were smaller, but still remained at the appropriate level. 
That indicates the advantage of this mechanism. In addition, the number of units of insulin 
administered was lower in the case of "artificial pancreas" (32.2 [6.4] units, P <.01) than in the case 
of traditional pumps (38.0 [5.7] units, P <.01).  
 
Biomaterials in pancreatic islets transplants 
Due to the significant limitations of pancreatic islet transplantation associated with cell destruction 
during isolation and the small number of donors, effective methods of culturing and surgeries are 
still sought. Promising results were observed during co-cultivation of harvested pancreatic cells 
along with adipose-derived stem cells (ADSCs). The study showed that joint storage of these cells 
causes pancreatic islets to change their morphology. As a result, they are less susceptible to the 
adverse effects of external factors and also secrete more insulin in comparison to cells from 
individual culture. A similar relationship regarding the positive effects of co-culture was noted 
when hybrids were formed from pancreatic cells and hepatocytes. The functions of pancreatic cells 
were monitored by assessing insulin secretion and hepatic cells based on albumin, urea secretion 
and cytochrome P450 activity. After 4 weeks, a two-way advantage was observed in the above-
mentioned parameters in relation to the individual cultures of these two cell types
42
. 
 
Patient-doctor contact 
Mobile applications in the doctor-patient relationship play an increasingly important role. There are 
many glucose meters on the market connecting to the application on the phone. The more advanced 
measurement methods listed above are based entirely on the operation of the computer or telephone 
application. Obviously, it is easier to download automatically the results and be sure that the 
patients glucose measurements are real. An additional role is played by applications for monitoring 
physical effort. Due to various types of bands and watches, the doctor can assess not only the 
patient's physical activity, but also the caloric balance, heart rate and more. These can be parameters 
that objectively assess the patients physical activity translating into the degree of compliance with 
recommendations and the actual change in lifestyle. Research shows that such applications are a 
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motivation for physical effort. They help in starting physical activity, as well as in maintaining 
regular workouts
43
. 
 
Conclusion 
The article describes many methods that patients with diabetes already have access to or will use in 
the coming years. It applies to both diagnostic and therapeutic methods. Artificial pancreas already 
imitate the action of natural organs. It is possible that soon thanks to miniaturization, 
nanotechnology and the development of biomaterials, a more perfect device will appear. It will not 
require wearing an injection or insulin pump on the strap that undoubtedly will improve the comfort 
of people with diabetes. Medical personnel should follow innovations appearing on the market to be 
able to provide patients with the highest comfort of therapy. Perhaps, according to the predictions of 
authorities such as Yuval Noah Harari
44
, who extends the vision of man evolving with technology, 
man will become a "biological machine". It will happen that we will modify our own bodies not 
with implants treating disease or disability, but with implants improving the quality of life of a 
healthy person. In the twenty-first century, the challenge is on the side of both the doctor and 
patient, so that in cooperation they can maximize the potential of new technologies and contribute 
to the development of medicine. 
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